FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising a single-stranded nucleic molecule that inhibits the expression of the prorenin gene or the prorenin receptor gene, a prorenin gene expression inhibitor or prorenin receptor gene, a therapeutic agent for eye diseases containing said nucleic acid molecule, a method of inhibiting prorenin gene expression or prorenin receptor gene involving using said nucleic acid molecule, use of said nucleic acid molecule for producing a prorenin gene expression inhibitor or prorenin receptor gene.
EFFECT: invention extends the range of agents for inhibiting prorenin expression gene or prorenin receptor gene.
24 cl, 14 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NATURALLY OCCURRING IN NATURE SIRNA TO CONTROL GENE EXPRESSION AND USE THEREOF | 2015 |
|
RU2740032C2 |
| COMPOSITION STABLY CONTAINING A NUCLEIC ACID MOLECULE | 2015 |
|
RU2723032C2 |
| SINGLE-CHEMICAL NUCLEIC ACID MOLECULES FOR GENE EXPRESSION CONTROL | 2011 |
|
RU2628311C2 |
| ARTIFICIAL GENOME MODIFICATION FOR GENE EXPRESSION REGULATION | 2018 |
|
RU2767201C2 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
| CHIMERIC OSPA GENES, PROTEINS AND THEIR APPLICATION METHODS | 2011 |
|
RU2773402C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
